DMHA and higenamine are two ingredients that moved from obscurity to enforcement targets after they were found in supplements without adequate safety histories. DMHA, a synthetic stimulant chemically similar to the banned DMAA, appeared in pre-workout products in 2014 and was later addressed by FDA warning letters; per a 2021 analysis by Cohen and colleagues in JAMA, higenamine — a plant compound that acts as a beta-2 agonist — was found in weight-loss supplements at doses that varied many-fold between products, sometimes exceeding amounts used in any studied context. Both are prohibited in sport; higenamine sits in the World Anti-Doping Agency's beta-2 agonist class.
24 News Click publishes information, not medical advice. Questions about stimulant safety belong with a qualified clinician.
Where did DMHA come from?
DMHA (1,5-dimethylhexylamine, also marketed as 2-aminoisoheptane or by plant-sourced names) followed DMAA's playbook. DMAA had been marketed as a natural geranium constituent; the FDA's position, stated in its public actions beginning in 2012, was that DMAA was not a lawful dietary ingredient and that evidence for its natural presence in geranium was lacking, and the agency later linked it to serious adverse events. When DMAA was forced off the market, structurally similar stimulants appeared in its place. DMBA appeared in 2014 products, per the Cohen analysis in Drug Testing and Analysis, and DMHA followed in subsequent years. Per FDA warning letters sent in later enforcement rounds, the agency's stated position is that DMHA does not qualify as a lawful dietary ingredient — it is not an approved food additive, and the agency did not accept it as a pre-1994 ingredient.
The pattern has a name in the regulatory literature: ingredient whack-a-mole. Each substitution is chemically new, untested in humans, and marketed with the same energy-and-focus claims until enforcement catches up.
What is higenamine?
Higenamine is a real plant constituent, found in several traditional-medicine plants such as nandina and aconite relatives. That botanical pedigree does not make it benign: pharmacologically it is a beta-2 agonist, the same drug class as clenbuterol and certain asthma inhalers, and WADA prohibits beta-2 agonists with narrow, well-defined inhalation exceptions. A compound's class determines its status in sport, not whether a label calls it herbal.
The 2021 JAMA analysis by Cohen and colleagues documented the second problem: dosing chaos. Across products listing higenamine, the per-serving amounts varied widely — the analysis reported a many-fold range, with some products delivering amounts far above those in any published human study. A prohibited-class compound, at unstandardized doses, sold over the counter as a fat burner, is a precise summary of what the analysis found.
What do these ingredients actually do?
Both are stimulants, and users report the expected subjective effects — alertness, elevated heart rate, perceived energy. The honest evidentiary statement is short: neither DMHA nor higenamine has a meaningful body of human efficacy or safety research at the doses sold. Beta-2 agonists as a class carry documented cardiac effects at sufficient doses, which is part of why the class is prohibited in sport and tightly controlled in medicine. Marketing claims about enhanced fat loss or workout intensity for these specific ingredients are not supported by controlled trials; they are borrowed from the general stimulant experience.
How do they hide on labels?
The recurring concealment routes are three. Chemical-synonym labeling — the same compound under half a dozen names, with DMHA's synonyms illustrating the problem. Proprietary blends, where the compound may appear under an unfamiliar name inside a blend total, or not appear at all. And botanical fronting, where a plant name (geranium extract, aconite extract) stands in for the active synthetic or concentrated compound. The FDA's position in its warning letters has consistently been that a substance does not become a lawful dietary ingredient by being attached to a plant name.
What reduces the risk?
The tools are the same as for contamination generally, sharpened for stimulants. Third-party batch certification screens for prohibited substances per batch, per the published scopes of NSF Certified for Sport and Informed Sport. WADA's prohibited list and its Global DRO database let athletes check named substances, though only certification addresses undeclared contents. And a short list of red flags catches most cases: unfamiliar stimulant names on a pre-workout label, geranium or plant-extract energy claims, and any weight-loss product whose effects feel distinctly pharmaceutical. The National Institutes of Health Office of Dietary Supplements publishes ingredient fact sheets covering the better-studied compounds — and the absence of a fact sheet is itself information.
How do athletes check an ingredient against the prohibited list?
WADA publishes the Prohibited List annually, effective each January 1, and its Global DRO reference service lets users search named substances by category. The check works only for named ingredients — an athlete can verify that higenamine is prohibited as a beta-2 agonist in seconds. It cannot reveal an ingredient hidden under a synonym or absent from the label entirely, which is why anti-doping organizations pair list-checking with batch certification rather than treating either as sufficient alone.
Were DMHA products ever recalled?
Enforcement ran through warning letters and import alerts rather than a single sweeping recall, per the FDA's public actions. Companies that received letters over DMHA generally reformulated or discontinued the named products; others relabeled the same compound under alternative names, which is the documented pattern the regulatory literature describes. The absence of a headline recall does not indicate the ingredient was cleared — the agency's stated position against its use as a dietary ingredient stands in the warning-letter record.
What replaced DMHA?
The honest answer is that the substitution cycle continues faster than pharmacology can track it. After DMAA came DMBA, after DMBA came DMHA, and analyses of pre-workout and weight-loss products continue to surface novel stimulants with no human testing history. This is why ingredient-by-ingredient education has limits as a strategy: a shopper cannot memorize an open-ended list. The structural defenses — batch certification, suspicion of unfamiliar stimulant names, and avoidance of the categories where substitution is routine — are durable precisely because they do not depend on knowing the current compound's name.
Are energy drinks affected too?
The same chemistry appears across the stimulant-product spectrum, though regulatory treatment differs by category. Conventional energy drinks are regulated as beverages with caffeine limits and labeling rules; supplements and powders follow the dietary-supplement framework, where the novel-stimulant substitutions documented in the warning-letter record occurred. The ingredient names change faster than any category boundary, so the practical rule — treat unfamiliar stimulant names as a flag — applies regardless of whether the product is sold as a drink, powder, or capsule.
FAQ
Is DMHA banned?
In sport, yes — it is prohibited as a stimulant under the WADA framework. In the US market, per FDA warning letters, the agency's stated position is that DMHA does not qualify as a lawful dietary ingredient, making products containing it unlawfully marketed.
Is higenamine natural, and does that matter?
Higenamine occurs in plants, but it is a beta-2 agonist — a drug class prohibited in sport with narrow exceptions. A 2021 JAMA analysis found its doses in supplements varied many-fold between products, beyond anything studied in humans.
How can these stimulants be spotted on a label?
Often they cannot be — synonyms, blends and plant-extract names conceal them. Batch certification with banned-substance screening is the only consumer check that addresses undeclared or renamed contents.
For more context, read Contamination and banned substances in supplements: what the data show.
For more context, read pre-workout label accuracy.
For more context, read How FDA supplement warning letters actually work.